Biosimilars Trigger Analytical Frenzy as Innovators Look to Update Methods
This article was originally published in The Gold Sheet
As biosimilar developers ‘fingerprint’ molecules with state-of-the-art assays in hopes of winning reduced clinical trials or more, innovators are updating their analytical methods, hoping to alert FDA before their competitors about any issues the old methods may have missed. As the ‘totality of the evidence’ on their molecules increases exponentially, concerns are raised about the proliferation of non-critical specifications.
You may also be interested in...
The agency’s first three draft guidances on biosimilar product development describe how to characterize biosimilar and reference products and extrapolate data on one condition of use to another. FDA says interchangeability is difficult to determine now and will require a switching study.
A fresh executive order from US president Joe Biden calls for short-term and long-term study, broad consultation, and co-ordination with allies on the domestic supply chain.
Executive order calls for short-term and long-term study, broad consultation, coordination with allies.